Showing 8281-8290 of 8647 results for "".
- Melt Pharmaceuticals Improves Patent Estate for Sublingual Non-Opioid Pain and Sedation Formulationshttps://modernod.com/news/melt-pharmaceuticals-improves-patent-estate-for-sublingual-non-opioid-pain-and-sedation-formulations/2476298/Melt Pharmaceuticals, a specialty pharmaceutical company recently deconsolidated from Harrow Health, announced the U.S. Patent and Trademark office has issued two additional patents covering the company’s innovative sublingual, non-opioid pain and sedation formulations. U.S. Patents 10,16
- Ophtec’s Precizon Presbyopic IOL with Continuous Transitional Focus (CTF) Optic Now Patented in the UShttps://modernod.com/news/ophtecs-precizon-presbyopic-iol-with-continuous-transitional-focus-ctf-optic-now-patented-in-the-us/2476299/Ophtec was granted a patent by the US patent office for its Continuous Transitional Focus (CTF) optical design of the new aspheric presbyopia correcting IOL. This new generation of multifocal IOLs for the treatment of cataracts, called “Precizon Presbyopic,” allows patients to experie
- Neurotech Pharmaceuticals Granted Fast Track Designation from the FDA for the Treatment of Macular Telangiectasia Type 2https://modernod.com/news/neurotech-pharmaceuticals-granted-fast-track-designation-from-the-fda-for-the-treatment-of-macular-telangiectasia-type-2/2476300/Neurotech Pharmaceuticals announced that the FDA has granted Fast Track designation for the company’s development candidate, NT-501 or Renexus, for the treatment of macular telangiectasia type 2 (MacTel). Fast track is a designation by the FDA to facilitate the development and expedite the
- Pr3vent Completes Series A Financing Led By InFocus Capital Partnershttps://modernod.com/news/pr3vent-completes-series-a-financing-led-by-infocus-capital-partners/2476301/Pr3vent, a healthcare AI company developing machine vision for detecting eye disease in newborns, has closed a Series A financing led by InFocus Capital Partners. The announcement comes on the heels of a successful seed round in October 2018 led by the joint investment of Skyview Ventures and Tro
- Retreatment With A Single TearCare Treatment Continues To Provide Relief For Patients With Dry Eye Diseasehttps://modernod.com/news/retreatment-with-a-single-tearcare-treatment-continues-to-provide-relief-for-patients-with-dry-eye-disease/2476302/A new, single center, prospective clinical study published in the January issue of Clinical Ophthalmology provides preliminary evidence that retreatment with the Sight Sciences TearCare System is a safe and effective treatment for dry eye disease, according to a company news release. The
- One-Year Results from Phase 3 Eylea Trial in Diabetic Retinopathy Presentedhttps://modernod.com/news/one-year-results-from-positive-phase-3-eylea-trial-in-diabetic-retinopathy-presented-at-angiogenesis-symposium/2476306/Regeneron Pharmaceuticals announced that positive detailed 1-year results from the phase 3 PANORAMA trial evaluating Eylea (aflibercept) injection in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR)
- Optical and Ophthalmology Cloud Solutions Provider KIDE Systems Becomes Topcon Healthcare Solutions EMEAhttps://modernod.com/news/optical-and-ophthalmology-cloud-solutions-provider-kide-systems-becomes-topcon-healthcare-solutions-emea/2476307/Following Topcon Healthcare Solutions’ acquisition of KIDE Systems in April 2018, KIDE Systems announced that it will take on the branding of its parent company Topcon Healthcare Solutions, part of Topcon Corporation. The brand change includes the change of KIDE System’s corporate name to Topcon
- Topcon Healthcare Solutions and Oculo Form Global Partnershiphttps://modernod.com/news/topcon-healthcare-solutions-and-oculo-form-global-partnership/2476308/Topcon Healthcare Solutions (THS) and Oculo, a technology provider in clinical communications based out of Melbourne, Australia, have announced a new partnership that will combine the strengths of their Topcon Harmony and Oculo eye care platforms. Financial terms of the deal were not disc
- EU-5 Ophthalmic Market Will Top $10 Billion in 2023https://modernod.com/news/eu-5-ophthalmic-market-will-top-10-billion-in-2023/2476311/Market Scope expects growing demand for retinal pharmaceuticals to help manufacturers’ ophthalmic revenues top $10 billion in 2023 in the five largest economies of the European Union. The ophthalmic markets in France, Germany, Italy, Spain, and the UK––the five countries that made up
- Regeneron Q4 Earnings & Sales Beat on Strong Eylea Saleshttps://modernod.com/news/regeneron-q4-earnings-sales-beat-on-strong-eylea-sales/2476314/Regeneron Pharmaceuticals delivered impressive results in the fourth quarter of 2018 wherein both earnings and sales beat estimates, according to a Nasdaq report. Shares ar